Diederik De Cock Selected Research

Necrosis

10/2022	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
1/2020	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diederik De Cock Research Topics

Disease

21	Rheumatoid Arthritis 10/2022 - 01/2015
5	Pain (Aches) 10/2022 - 01/2021
4	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2021 - 01/2019
3	Fatigue 10/2022 - 01/2021
2	Necrosis 10/2022 - 01/2020
2	Rheumatic Diseases (Rheumatism) 01/2020 - 01/2019
2	Infections 01/2019 - 01/2018
1	Arthritis (Polyarthritis) 10/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Asthenopia (Eyestrain) 01/2021
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2021
1	Uveitis 01/2020
1	Drug-Related Side Effects and Adverse Reactions 03/2019
1	Phobic Disorders (Phobia) 03/2019
1	Exanthema (Rash) 03/2019
1	Drug Hypersensitivity (Drug Allergy) 03/2019
1	Leukopenia 03/2019
1	Macrophage Activation Syndrome 01/2019
1	Neoplasms (Cancer) 12/2018
1	Joint Diseases (Joint Disease) 03/2017

Drug/Important Bio-Agent (IBA)

11	GlucocorticoidsIBA 06/2021 - 01/2015
9	Methotrexate (Mexate)FDA LinkGeneric 06/2021 - 04/2015
6	Biological ProductsIBA 01/2020 - 10/2018
5	Antirheumatic Agents (DMARD)IBA 10/2022 - 01/2015
4	Rituximab (Mabthera)FDA Link 01/2020 - 01/2017
3	Leflunomide (Arava)FDA LinkGeneric 09/2020 - 01/2020
2	Abatacept (Orencia)FDA Link 10/2022 - 01/2020
2	Janus Kinase InhibitorsIBA 10/2022 - 01/2020
2	Tumor Necrosis Factor InhibitorsIBA 10/2022 - 01/2019
2	ametantrone (HAQ)IBA 10/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
2	C-Reactive ProteinIBA 01/2021 - 03/2017
2	Tramadol (K315)FDA LinkGeneric 01/2021 - 01/2021
2	Opioid Analgesics (Opioids)IBA 01/2021 - 01/2021
2	Adalimumab (Humira)FDA Link 01/2020 - 01/2020
2	Etanercept (Enbrel)FDA Link 01/2020 - 01/2020
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 01/2020
2	Infliximab (Remicade)FDA Link 01/2020 - 01/2020
2	tocilizumab (atlizumab)FDA Link 01/2020 - 01/2019
1	Interleukin-6 InhibitorsIBA 10/2022
1	Prostaglandins AIBA 10/2022
1	Indicators and Reagents (Reagents)IBA 04/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	GLPG0634IBA 01/2020
1	baricitinibIBA 01/2020
1	upadacitinibIBA 01/2020
1	tofacitinibIBA 01/2020
1	golimumab FDA Link 01/2020
1	sarilumabIBA 01/2020
1	Certolizumab Pegol FDA Link 01/2020
1	Janus KinasesIBA 01/2020
1	Biosimilar PharmaceuticalsIBA 01/2020
1	EnzymesIBA 03/2019
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2019

Therapy/Procedure

5	Therapeutics 10/2022 - 01/2015
3	Remission Induction 01/2020 - 01/2015
1	Ambulatory Care (Outpatient Care) 08/2021
1	Aftercare (After-Treatment) 01/2020